Gazyva (obinutuzumab) / Nippon Shinyaku, Biogen, Roche 
Welcome,         Profile    Billing    Logout  

210 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gazyva (obinutuzumab) / Roche, Biogen
NCT06454968: Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.

Recruiting
2
45
RoW
Orelabrutinib, obinutuzumab, lenalidomide
Peking Union Medical College Hospital
Marginal Zone Lymphoma
06/26
06/28
NCT06295770: Obinutuzumab in Treatment of Fibrillary Glomerulonephritis

Recruiting
2
20
US
Obinutuzumab, Gazyva
Mayo Clinic
Fibrillary Glomerulonephritis
05/26
05/26
SWOG S1608, NCT03269669: Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

Recruiting
2
95
US
Bendamustine Hydrochloride, Belrapzo, Bendamustin Hydrochloride, Bendeka, CEP-18083, Cytostasan Hydrochloride, Levact, Ribomustin, SyB L-0501, Treakisym, Treanda, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Echocardiography, EC, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Umbralisib, 2-((1S)-1-(4-Amino-3-(3-fluoro-4-(1-methylethoxy)phenyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-1-benzopyran-4-one, RP-5264, RP5264, TGR-1202, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
National Cancer Institute (NCI)
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma
12/25
12/25
NCT06474481: Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular Lymphoma

Not yet recruiting
2
30
NA
Zanubrutinib, Obinutuzumab, Prednisone, Cyclophosphamide, Vincristine, Doxorubicin
Tianjin Medical University Cancer Institute and Hospital
FL
12/27
12/29
NCT02871219: Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma

Active, not recruiting
2
96
US
Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Ann Arbor Stage II Grade 1 Follicular Lymphoma, Ann Arbor Stage II Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Bulky Disease, Fatigue, Fever, Grade 3a Follicular Lymphoma, Night Sweats, Splenomegaly, Weight Loss
07/24
07/24
NCI-2021-12489, NCT05169658: Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma

Recruiting
2
42
US
Mosunetuzumab, 1905409-39-3, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A, BTCT 4465A, BTCT-4465A, BTCT4465A, CD20/CD3 BiMAb BTCT4465A, RG 7828, RG-7828, RG7828, RO7030816, Lunsumio, Mosunetuzumab-axgb, Obinutuzumab, 949142-50-1, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Polatuzumab Vedotin, 1313206-42-6, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, polatuzumab vedotin-piiq, Polivy, RG7596, Ro 5541077-000
University of Washington, Genentech, Inc.
Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Marginal Zone Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
12/25
12/25
O-ICE, NCT02393157: Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

Recruiting
2
25
US
Obinutuzumab, Gazyva, Liposomal ARA-C, Depocyte, Ifosfamide, Ifex, Carboplatin, Paraplatin, Etoposide, VP-16
New York Medical College, Roswell Park Cancer Institute
Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Primary Mediastinal B-cell Lymphoma, CD20+ Lymphoblastic Lymphoma, Follicular Lymphoma, Grade III
12/24
12/24
UPCC 48420, NCT04889716: CAR-T Followed by Bispecific Antibodies

Recruiting
2
42
US
mosunetuzumab, RO7030816, BTCT4465A, Lunsumio, glofitamab, CD20 TCB, RO7082859, obinutuzumab, Gazyva, Gazyvaro, RO5072759, huMAb , GA101
Abramson Cancer Center at Penn Medicine, Genentech, Inc.
Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma
12/24
12/25
NCT05336812: Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

Recruiting
2
52
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
Ohio State University Comprehensive Cancer Center
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
12/24
12/24
NCT05376319: PR3-AAV Resilient Remission or PRRR

Terminated
2
6
US
Obinutuzumab, Rituximab
Mayo Clinic, Genentech, Inc.
Granulomatosis With Polyangiitis, Microscopic Polyangiitis, ANCA Associated Vasculitis
05/24
05/24
NCT03824483: Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

Recruiting
2
230
US
Zanubrutinib, Obinutuzumab, GA101, Venetoclax, ABT-199
Memorial Sloan Kettering Cancer Center, BeiGene USA, Inc., Roche-Genentech, Massachusetts General Hospital
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL)
02/25
02/25
NCT04722172: A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL

Active, not recruiting
2
55
US
Acalabrutinib, Obinutuzumab
Memorial Sloan Kettering Cancer Center, AstraZeneca, Genentech, Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
02/25
02/25
ReVenG, NCT04895436 / 2021-001037-39: Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

Recruiting
2
75
Europe, US, RoW
Venetoclax, Venclexta, ABT-199, GDC-0199, Obinutuzumab, GA101, Gazyva
AbbVie, F. Hoffmann-La Roche Ltd; German CLL Study Group (GCLLSG); Dana-Farber Cancer Institute
Chronic Lymphocytic Leukemia (CLL)
02/25
01/29
CWCLL-001, NCT05322733: Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL

Recruiting
2
25
RoW
Orelabrutinib, ICP-022, Obinutuzumab, GA101, Fludarabine, Fludara, Cyclophosphamide
The First Affiliated Hospital with Nanjing Medical University
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
02/25
11/25
NCT02846623: Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome

Recruiting
2
65
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Laboratory Biomarker Analysis, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter Syndrome, Small Lymphocytic Lymphoma
02/25
02/25
NCT04560322: Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

Recruiting
2
40
US
Venetoclax, Venclexta, Obinutuzumab, Gazyva, Acalabrutinib, Calquence
Massachusetts General Hospital, Genentech, Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
03/25
03/25
NCT03516617: Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recruiting
2
120
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Laboratory Biomarker Analysis, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Patient Observation, Active Surveillance, deferred therapy, expectant management, Observation, Watchful Waiting, Quality-of-Life Assessment, Quality of Life Assessment
Mayo Clinic, National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
03/25
03/26
NCT02629809: Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia

Active, not recruiting
2
81
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759
M.D. Anderson Cancer Center
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
03/25
03/25
CLL2-BZAG, NCT04515238: Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL

Active, not recruiting
2
42
Europe
Bendamustine, Treanda, Bendeka, Obinutuzumab, GA101, Gazyvaro, Zanubrutinib, BGB-3111, Venetoclax, ABT-199, Venclyxto
German CLL Study Group
Chronic Lymphoid Leukemia
04/25
03/27
ORION, NCT05050214: Obinutuzumab in Primary MN

Active, not recruiting
2
20
Europe
Obinutuzumab, GAZYVA, GAZYVARO
Mario Negri Institute for Pharmacological Research, Roche Pharma AG
Membranous Nephropathy
04/25
04/25
NCI-2022-07625, NCT05536349: Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

Recruiting
2
60
US
Pirtobrutinib, Obinutuzumab, GA101, Gazyva, RO5072759, Venetoclax, ABT-199, GDC-0199, Valacyclovir, Allopurinol
M.D. Anderson Cancer Center, Loxo Oncology, Inc., The Leukemia and Lymphoma Society
Leukemia
04/25
04/25
NCT04983888: Obinutuzumab in Primary FSGS

Active, not recruiting
2
20
US
Obinutuzumab
Mayo Clinic, Genentech, Inc.
Primary Focal Segmental Glomerulosclerosis
06/25
09/25
FLMRD, NCT04934930: Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease Status

Recruiting
2
40
RoW
Bendamustin, Ribomustin, Obinutuzumab, Gazyva
Meir Medical Center, Rabin Medical Center, Tel-Aviv Sourasky Medical Center, Assuta Ashdod Hospital, Ziv Medical Center
Follicular Lymphoma
08/25
08/25
2023CD20ITP, NCT05995054: A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Immune Thrombocytopenia

Recruiting
2
110
RoW
Obinutuzumab Injection [Gazyva]
Institute of Hematology & Blood Diseases Hospital
Immune Thrombocytopenia, Treatment
08/25
08/26
NCT05105841: Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
2
20
Japan
Venetoclax, Venclexta, ABT-199, GDC-0199, Ibrutinib, Imbruvica, Obinutuzumab, GA101, Gazyva, RO5072759
AbbVie
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
10/25
10/25
VIS, NCT05478512: Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL

Recruiting
2
78
Europe
VenObi+Ven or VenObi+VenZan
Gruppo Italiano Malattie EMatologiche dell'Adulto
High Risk CLL, Chronic Lymphocytic Leukemia
05/26
07/27
NCT06094881: A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)

Recruiting
2
60
RoW
Obinutuzumab Injection [Gazyva]
Institute of Hematology & Blood Diseases Hospital, China
Immune Thrombocytopenia, Treatment
11/25
11/26
NEXT STEP, NCT04639362 / 2019-002528-34: CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.

Active, not recruiting
2
85
Europe
ibrutinib, venetoclax, obinutuzumab, Intensification, ibrutinib, venetoclax, Observation
Stichting Hemato-Oncologie voor Volwassenen Nederland, Nordic Lymphoma Group
CLL
12/25
12/28
NCT06108232: Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma

Recruiting
2
36
US
Obinutuzumab, GA101, Gazyva, RO5072759, CC-99282
M.D. Anderson Cancer Center, Bristol-Myers Squibb
Follicular Lymphoma, Tumor
12/25
12/27
NCT05783596: Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma

Recruiting
2
50
US
Obinutuzumab, RO5072759, GA101, GAZYVA, GAZYVARO, Glofitamab, RO7082859
Reid Merryman, MD, Genentech, Inc.
Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma
01/26
01/29
ChiCTR2300071433: Clinical trial of Zanubrutinib With Obinutuzumab as First-Line Treatment in Older Patients With Mantle Cell Lymphoma

Not yet recruiting
2
48
 
Zanubrutinib with Obinutuzumab
The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University; The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, NA
Mantle Cell Lymphoma
 
 
POSTERITY, NCT05039619 / 2021-000097-29: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

Recruiting
2
40
Europe, Canada, US, RoW
Obinutuzumab, Gazyva, Placebo, Mycophenolate Mofetil, Acetaminophen/paracetamol, Diphenhydramine hydrochloride (HCl), Methylprednisolone, Prednisone
Hoffmann-La Roche, Genentech, Inc.
Lupus Nephritis
03/26
03/29
NCT05846750: Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma

Recruiting
2
59
RoW
Obinutuzumab, GA101, lenalidomide
Institute of Hematology & Blood Diseases Hospital
Marginal Zone Lymphoma
05/26
05/28
NCT04447768: The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)

Active, not recruiting
2
100
US
Obinutuzumab, Venetoclax
Memorial Sloan Kettering Cancer Center, Genentech, Inc.
Chronic Lymphocytic Leukemia (CLL)
07/26
07/26
NCT04169737: Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recruiting
2
168
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
07/26
07/26
MOLTO, NCT04082897 / 2018-005028-40: ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation

Active, not recruiting
2
28
Europe
Obinutuzumab 25 MG/ML [Gazyva], Atezolizumab 60 MG/ML [Tecentriq], Venetoclax Oral Tablet
Niguarda Hospital
CLL Transformation
09/26
12/26
FIGHT, NCT04908228: Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLL

Recruiting
2
53
Europe
Ibrutinib and obinutuzumab, Imbruvica and Gazyvaro
Paolo Ghia
Chronic Lymphocytic Leukemia
09/26
09/27
NCI-2023-06838, NCT06054776: Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Recruiting
2
40
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Echocardiography, EC, Glofitamab, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody RO7082859, RO 7082859, RO7082859, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
City of Hope Medical Center, National Cancer Institute (NCI)
Mantle Cell Lymphoma
09/26
09/26
BruVenG, NCT05650723: Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab

Recruiting
2
50
US
Zanubrutinib Pill, Brukinsa, Venetoclax Pill, Venclexta, Obinutuzumab Injection, Gazyva
Weill Medical College of Cornell University, BeiGene, Genentech, Inc.
Leukemia, Lymphocytic, Chronic, B-Cell
01/25
12/27
R-Pola-Glo, NCT05798156: Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP

Recruiting
2
80
Europe
Glofitamab, Rituximab, Obinutuzumab, Polatuzumab vedotin
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Charite University, Berlin, Germany, University of Salzburg, Arbeitsgemeinschaft medikamentoese Tumortherapie, Roche Pharma AG, Zentrum für Klinische Studien Leipzig, Hoffmann-La Roche
Lymphoma, Large B-Cell, Diffuse
09/27
09/28
NCT06043674: A Ph 2 Study of Glofitamab Alone or in Combination With Polatuzumab Vedotin or Atezolizumab in Richter's Transformation

Recruiting
2
66
US
Glofitamab, RO7082859, Obinutuzumab, RO5072759, GA101, GAZYVA, GAZYVARO, Polatuzumab Vedotin, Atezolizumab, Tecentriq, Tocilizumab, Actemra
Christine Ryan, Genentech, Inc.
Chronic Lymphocytic Leukemia, Richter's Transformation
01/28
01/33
PORTAL, NCT06071871: A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab as a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma

Not yet recruiting
2
99
NA
Glofitamab, Columvi, Polatuzumab vedotin, Polivy, Obinutuzumab, Gazyvaro
University College, London, Hoffmann-La Roche
Large B-cell Lymphoma
01/27
07/28
REFRACT, NCT05848765: Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

Recruiting
2
284
Europe
Epcoritamab, Lenalidomide, Rituximab, Obinutuzumab, Bendamustine, Vincristine, Doxorubicin, Cyclophosphamide, Prednisone, Investigation agent 2, Investigation agent 3
University of Birmingham, Cancer Research UK, Genmab
Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma
05/29
11/31
GOlDiLOX, NCT05833763: A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.

Recruiting
2
42
RoW
Glofitamab, Pirtobrutinib, Obinutuzumab, Tocilizumab
Australasian Leukaemia and Lymphoma Group
Mantle Cell Lymphoma, Mantle Cell Lymphoma Refractory
04/32
04/37
NCT01582776 / 2011-005150-62: Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma

Completed
1/2
317
Europe
Lenalidomide and GA101, Revlimid, Obinutuzumab
The Lymphoma Academic Research Organisation
Follicular Lymphoma Patients (Phase IB), Follicular and Agressive (DLBCL&MCL) B-cell Lymphoma Patients (Phase II)
07/18
05/22
OAsIs, NCT02558816 / 2014-003740-13: A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients

Active, not recruiting
1/2
48
Europe
Ibrutinib + GA101 +GDC-0199, GA101 : Obinutuzumab, Ibrutinib, GDC-0199
Nantes University Hospital, Janssen, LP, Roche Pharma AG
Mantle Cell Lymphoma
04/19
10/25
2020-000354-10: A study to evaluate how safe is CC-220, how is the body affected by CC-220, and a preliminary idea on how CC-220 works, when given alone or together with a medicine to treat cancer, in patients with lymphoma that is not responding to treatment or that has re-appeared.

Not yet recruiting
1/2
232
Europe
Iberdomide, CC-220, Concentrate for concentrate for solution for infusion, Solution for injection, Capsule, hard, Mabthera, Gazyvaro
Celgene Corporation, Celgene Corporation
Relapsed or refractory lymphoma including the following subtypes:Aggressive B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma and classical Hodgkin lymphoma., Different forms of type of blood cancer, called lymphoma, that is not responding to treatment or that has re-appeared., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2019-003456-36: A study of PRS-344/S095012 (PD-L1x4-1BB bispecific antibody) in patients with solid tumors

Not yet recruiting
1/2
277
Europe
S095012, S095012, Concentrate for solution for infusion, Gazyvaro®
Institut de Recherches Internationales Servier, ADIR, Laboratorios Servier S. L.
Advanced and/or metastatic solid tumors, Solid tumors, Diseases [C] - Cancer [C04]
 
 
2018-003235-29: An early study to investigate a new medicine for Subjects with Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Not yet recruiting
1/2
348
Europe
CC-99282, Gazyvaro, Tafasitamab, Rituximab, valemetostat, CC-99282, Capsule, Concentrate for solution for infusion, Concentrate and solvent for solution for infusion, Tablet, MabThera 100 mg concentrate for solution for infusion, Gazyvaro, Monjuvi
Celgene Corporation, Celgene Corporation
Subjects with R/R NHL, which includes diffuse large B-cell lymphoma (DLBCL) (not otherwise specified [NOS] or transformed), FL (follicular lymphoma), mantle cell lymphoma (MCL), primary central nervous system lymphoma (PCNSL) or relapsed or refractory marginal zone lymphoma (MZL) who have failed at least 2 lines of therapy (or who have received at least one prior line of standard therapy and are not eligible for any other therapy)., Patients who have stopped responding or have failed to respond to treatment for cancer of a type of white blood cell., Diseases [C] - Cancer [C04]
 
 
NCT04464798: A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

Active, not recruiting
1/2
62
Europe, US, RoW
CC-220, Iberdomide, Rituximab, Obinutuzumab
Celgene
Lymphoma
03/23
01/25
NCT04722601: A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma

Terminated
1/2
2
US
Venetoclax, Venclexta, Venclyxto, Obinutuzumab, Gazyva, CC-486, azacitidine
University of Chicago
Follicular Lymphoma
03/23
03/23
OSU-14266, NCT02427451: Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia

Active, not recruiting
1/2
87
US
Bcl-2 Inhibitor GDC-0199, ABT-0199, ABT-199, GDC-0199, RG7601, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA101, Gazyva, R7159, RO 5072759, Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Pharmacological Study, pharmacological studies, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Quality of Life Assessment
Kerry Rogers
Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia
12/24
12/24
NCT02315768: Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.

Active, not recruiting
1/2
32
US
GA101, Obinutuzumab, ibrutinib
University of California, San Diego, Pharmacyclics LLC.
Chronic Lymphocytic Leukemia
11/23
11/23
NCT03492125: A Study Of The Selective PKC-β Inhibitor MS- 553

Recruiting
1/2
117
US
MS-553, acalabrutinib, venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, obinutuzumab, Gazyva
MingSight Pharmaceuticals, Inc
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma
04/24
06/24
NCT06357676: Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma

Not yet recruiting
1/2
27
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Echocardiography, EC, FDG-Positron Emission Tomography, FDG, FDG-PET, FDG-PET Imaging, Glofitamab, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody RO7082859, RO 7082859, RO7082859, Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759
OHSU Knight Cancer Institute, Oregon Health and Science University, Genentech, Inc.
Mantle Cell Lymphoma
05/27
05/29
ViPOR, NCT03223610: Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid () in Relapsed/Refractory B-cell Lymphoma

Recruiting
1/2
145
US
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, Revlimid (lenalidomide)
National Cancer Institute (NCI)
Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma
12/25
12/26
NP39488, NCT03533283: An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Active, not recruiting
1/2
280
Europe, US, RoW
Glofitamab, RO7082859, Atezolizumab, Obinutuzumab, Tocilizumab, Actemra, Polatuzumab Vedotin, 89Zr-Df-IAB22M2C
Hoffmann-La Roche
Non-Hodgkins Lymphoma
09/26
09/26
NCT06087419: A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients

Not yet recruiting
1/2
42
NA
chidamide, Venetoclax Oral Tablet, Inotuzumab Ozogamicin
Institute of Hematology & Blood Diseases Hospital, China
Acute Lymphoblastic Leukemia
12/24
12/25
NCT04855695: Avo In R/R And Previously Untreated MCL

Recruiting
1/2
53
US
Acalabrutinib, Calquence, Acalabrutinib maleate, Venetoclax, Venclexta, Obinutuzumab, Gazyva
Austin I Kim, AstraZeneca, Genentech, Inc.
Mantle Cell Lymphoma, Refractory Lymphoma
12/24
06/26
BP42675, NCT04826003: Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment

Active, not recruiting
1/2
80
Europe, RoW
RO7122290, Cibisatamab, Obinutuzumab
Hoffmann-La Roche
Metastatic Colorectal Cancer
12/24
12/24
NP30179, NCT03075696: A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Checkmark Data from P2 portion of P1/2 trial for DLBCL
Dec 2022 - Dec 2022: Data from P2 portion of P1/2 trial for DLBCL
Checkmark Data from trial for 3L+ LBCL at ASH 2022
Dec 2022 - Dec 2022: Data from trial for 3L+ LBCL at ASH 2022
Checkmark Safety and efficacy of phase 1/2 study for mantle cell lymphoma at ASH 2022
More
Recruiting
1/2
860
Europe, Canada, US, RoW
Glofitamab, RO7082859, Obinutuzumab, RO5072759, GA101, Gazyva®, Gazyvaro™, Tocilizumab, Actemra®, Roactemra®
Hoffmann-La Roche
Non-Hodgkin's Lymphoma
08/25
08/25
NCT02229422: A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 & HDMP)

Active, not recruiting
1/2
40
US
GA101/HDMP
University of California, San Diego, Genentech, Inc.
CLL
10/25
12/25
NCI-2023-03181, NCT05861050: Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

Recruiting
1/2
50
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Glofitamab, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody RO7082859, RO 7082859, RO7082859, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
City of Hope Medical Center, National Cancer Institute (NCI)
Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma
02/26
02/26
CC-99282-NHL-001, NCT03930953: A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Recruiting
1/2
438
Europe, Canada, US, RoW
CC-99282, BMS-986369, Rituximab, Obinutuzumab, Tafasitamab, Valemetostat
Celgene
Lymphoma, Non-Hodgkin
04/26
04/27
LEVERAGE, NCT03980171: Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma

Recruiting
1/2
61
US, RoW
Obinutuzumab, GAZYVA, GAZYVARO, Venetoclax, ABT-199 (A-1195425.0), Venclexta, Venclyxto, Lenalidomide, Revlimid
Peter MacCallum Cancer Centre, Australia
Follicular Lymphoma
11/26
11/26
C4971006, NCT05896163: A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.

Recruiting
1/2
70
Japan, US, RoW
maplirpacept (PF-07901801), Glofitamab, Obinutuzumab
Pfizer, Hoffmann-La Roche
Diffuse Large B-Cell Lymphoma
06/26
06/28
iMATRIX GLO, NCT05533775 / 2021-006326-48: A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

Recruiting
1/2
65
Europe, US, RoW
Obinutuzumab, Glofitamab, Rituximab, Ifosfamide, Carboplatin, Etoposide, Tocilizumab
Hoffmann-La Roche
Mature B-Cell Non-Hodgkin Lymphoma
10/27
10/27
NCT02417285: A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.

Checkmark For r/rNHL (DLBCL, FL and MZL) at ASH 2017 [screenshot]
Dec 2017 - Dec 2017: For r/rNHL (DLBCL, FL and MZL) at ASH 2017 [screenshot]
Checkmark In R/R DLBCL or iNHL at ASH 2016
Dec 2016 - Dec 2016: In R/R DLBCL or iNHL at ASH 2016
Completed
1b
75
Europe
Obinutuzumab, GA-101, CC-122
Celgene
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
05/19
09/23
NCT04434196: A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Active, not recruiting
1b
50
Europe, Canada, US
CC-99282, Obinutuzumab
Celgene
Lymphoma, Non-Hodgkin
11/24
05/25
KEYNOTE-E64, NCT04787042: Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

Recruiting
1a
316
US
ST-067, Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA], GAZYVA, pembrolizumab, KEYTRUDA
Simcha IL-18, Inc., Merck Sharp & Dohme LLC
Cancer, Solid Tumor, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Carcinoma, MSI-High
06/24
01/25
jRCT2080225077: A PHASE I STUDY OF RO7082859 IN PATIENTS WITH B-CELL NON-HODGKIN'S LYMPHOMA

Completed
1
12
Japan
Columvi (glofitamab) - Roche, Gazyva (obinutuzumab) - Roche, Biogen, Nippon Shinyaku, Actemra IV (tocilizumab) - Roche, JW Pharma
Chugai Pharmaceutical Co., Ltd.
 
 
NCT02339181: A Study of GDC-0199 (ABT-199) in Combination With Obinutuzumab in Patients With Chronic Lymphocytic Leukemia

Recruiting
1
70
US, Europe
GDC-0199 (ABT-199), Obinutuzumab
Hoffmann-La Roche, Accord Healthcare, Inc., AbbVie (prior sponsor, Abbott), Apotex Corporation, Alkem Laboratories Ltd
Lymphocytic Leukemia, Chronic
01/15
11/16
NCT02537613: A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Active, not recruiting
1
54
US
Obinutuzumab, Gazyva, GA-101, Ibrutinib, Imbruvica
Dana-Farber Cancer Institute, Genentech, Inc.
Chronic Lymphocytic Leukemia
03/20
01/29
ACE-CL-003, NCT02296918: Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL

Hourglass Jul 2022 - Dec 2022 : Data from trial for CLL/SLL/PLL
Checkmark From ACE-CL-003 trial in CLL/SLL/PLL
Jul 2021 - Jul 2021: From ACE-CL-003 trial in CLL/SLL/PLL
Checkmark Last patient dosing in P1 trial of acalabrutinib + obinutuzumab in CLL/SLL/PL
Feb 2019 - Feb 2019: Last patient dosing in P1 trial of acalabrutinib + obinutuzumab in CLL/SLL/PL
Active, not recruiting
1
69
US
acalabrutinib, ACP-196, Obinutuzumab, Gazyvaro, Venetoclax, ABT-199, Venclexta, GDC-0199, Rituximab, Rituxan
Acerta Pharma BV
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia
08/21
09/27
YO42610, NCT04657302: A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Completed
1
30
RoW
Obinutuzumab, Glofitamab, Tocilizumab
Hoffmann-La Roche
Lymphoma
10/22
01/24
NCT04245722: FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

Terminated
1
98
US
FT596, Cyclophosphamide, Fludarabine, Rituximab, Rituxan, Truxima, Ruxience, Obinutuzumab, Gazyva, Bendamustine, Bendeka, Treanda
Fate Therapeutics
Lymphoma, B-Cell, Chronic Lymphocytic Leukemia
09/23
09/23
FT516-101, NCT04023071: FT516 in Subjects With Advanced Hematologic Malignancies

Terminated
1
72
US
FT516, Rituximab, Rituxan, MabThera, Obinutuzumab, Gazyva, Cyclophosphamide, Fludarabine, IL-2, Bendamustine, Bendeka, Treanda
Fate Therapeutics
Acute Myelogenous Leukemia, B-cell Lymphoma
10/23
10/23
ISRCTN17975931: A study to evaluate the safety, tolerability, processing by the body, mechanism of action, and effectiveness of glofitamab following obinutuzumab pretreatment in patients with B-cell non-Hodgkin lymphoma

Recruiting
1
36
Australia, Belgium, Denmark, Italy, Poland, Spain, US
Gazyva (obinutuzumab) - Roche, Biogen, Nippon Shinyaku, Columvi (glofitamab) - Roche, dexamethasone - Generic mfg., Actemra IV (tocilizumab) - Roche, JW Pharma, Actemra SC (tocilizumab SC) - Roche, Halozyme
Genentech, Inc;Genentech, Genentech
B-cell non-Hodgkin lymphoma
 
 
NCT02992522: Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Active, not recruiting
1
22
US
Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta
Beth Christian, Celgene, Genentech, Inc.
B-Cell Lymphoma, Unspecified, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Transformed Recurrent Non-Hodgkin Lymphoma, B-Cell
12/24
12/24
NCT06192888: A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma

Recruiting
1
39
US
Glofitamab, Obinutuzumab, Lenalidomide
Memorial Sloan Kettering Cancer Center, Genentech, Inc.
Mantle Cell Lymphoma, MCL
01/28
01/28
NCT03866239: A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma

Completed
1
47
Europe, US
Obinutuzumab, Gazyva/Gazyvaro, Atezolizumab, Tecentriq, Cibisatamab, Tocilizumab
Hoffmann-La Roche
Colorectal Cancer
03/24
03/24
NCT05211336: Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System

Active, not recruiting
1
4
US
Obinutuzumab, Prednisone, Lenalidomide, Venetoclax, Ibrutinib
National Cancer Institute (NCI)
Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS
06/24
06/29
NCT04578600: CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

Active, not recruiting
1
8
US
Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Oral Azacitidine, CC-486
Joseph Tuscano, National Cancer Institute (NCI), Celgene
Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Mucosa-Associated Lymphoid Tissue Lymphoma, Recurrent Follicular Lymphoma, Recurrent Hairy Cell Leukemia, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Mucosa-Associated Lymphoid Tissue Lymphoma, Refractory Follicular Lymphoma, Refractory Hairy Cell Leukemia, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Small Lymphocytic Lymphoma
04/24
12/24
NCT06291220: A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Recruiting
1
80
US, RoW
Obinutuzumab, ABBV-453
AbbVie
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
07/29
07/29
GO43693, NCT05364424: A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma

Recruiting
1
40
US
Glofitamab, Obinutuzumab, Tocilizumab, Rituximab, Ifosfamide, Carboplatin, Etoposide
Hoffmann-La Roche
Diffuse Large B-Cell Lymphoma (DLBCL)
12/24
12/24
NCT04739813: Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

Recruiting
1
55
US
obinutuzumab, prednisone, Revlimid, Polatuzumab, ibrutinib, venetoclax
National Cancer Institute (NCI)
Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma
07/24
07/29
NCT05894447: Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers

Withdrawn
1
30
US
Naptumomab Estafenatox, Pembrolizumab, Keytruda, Obinutuzumab, Gazyva
Weill Medical College of Cornell University, NeoTX Therapeutics Ltd.
Urothelial Carcinoma
12/25
06/28
NP40126, NCT03467373: A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

Checkmark Safety and efficacy of phase 1 study in combination with R-CHOP in patients with previously untreated DLBCL
Dec 2022 - Dec 2022: Safety and efficacy of phase 1 study in combination with R-CHOP in patients with previously untreated DLBCL
Active, not recruiting
1
172
Europe, Canada, US, RoW
Glofitamab, RO7082859, Obinutuzumab (G), Gazyva, Rituximab (R), Rituxan, Tocilizumab, Actemra, Cyclophosphamide, Doxorubicin, Vincristine, Oncovin, Prednisone, Polatuzumab vedotin
Hoffmann-La Roche
B-Cell Lymphoma, Non-Hodgkin Lymphoma
10/24
10/24
NCT03198650: A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies

Hourglass Jul 2022 - Dec 2022 : Data from P1 tria for advanced B-cell malignancies
Checkmark In B-cell malignancies in Japanese adults
Mar 2021 - Mar 2021: In B-cell malignancies in Japanese adults
Active, not recruiting
1
35
Japan
Acalabrutinib, Obinutuzumab
AstraZeneca
Part1: Advanced B-cell Malignancies, Part2: r/rCLL and r/rMCL, Part3: Untreated CLL
10/22
12/24
LOTIS 7, NCT04970901: A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

Recruiting
1
200
Europe, US, RoW
Loncastuximab Tesirine, ZYNLONTA, ADCT-402, Polatuzumab Vedotin, Glofitamab, Mosunetuzumab, Obinutuzumab
ADC Therapeutics S.A.
B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
02/25
02/26
BP41072, NCT04077723: A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of RO7227166 in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab Administered in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Recruiting
1
498
Europe, US, RoW
RO7227166, A CD19 Targeted 4-1BB Ligand, Obinutuzumab, Gpt, RO5072759, Gazyva, Gazyvaro, Glofitamab, CD20-TCB, RO7082859, Tocilizumab, Actemra, RoActemra
Hoffmann-La Roche
Lymphoma, Non-Hodgkin
03/25
03/25
NCT03432741: Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Suspended
1
39
US
Belinostat, Beleodaq, PXD 101, PXD101, Carfilzomib, Kyprolis, PR-171, Copanlisib Hydrochloride, 5-Pyrimidinecarboxamide, 2-Amino-N-(2,3-dihydro-7-methoxy-8-(3-(4-morpholinyl)propoxy)imidazo(1,2-C)quinazolin-5-yl)-, Hydrochloride (1:2), Aliqopa, BAY 80-6946 Dihydrochloride, BAY-80-6946 Dihydrochloride, Copanlisib Dihydrochloride, Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, FF 10832, FF-10832, FF10832, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Laboratory Biomarker Analysis, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima, Romidepsin, Antibiotic FR 901228, Depsipeptide, FK228, FR901228, Istodax, N-[(3S,4E)-3-Hydroxy-7-mercapto-1-oxo-4-heptenyl]-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoyl-L-valine, (4->1) Lactone, Cyclic, Saline, ISOTONIC SODIUM CHLORIDE SOLUTION, Sodium Chloride 0.9%, Trastuzumab, ABP 980, ALT02, Anti-c-ERB-2, Anti-c-erbB2 Monoclonal Antibody, Anti-ERB-2, Anti-erbB-2, Anti-erbB2 Monoclonal Antibody, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-p185-HER2, c-erb-2 Monoclonal Antibody, HER2 Monoclonal Antibody, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Herzuma, Kanjinti, MoAb HER2, Monoclonal Antibody c-erb-2, Monoclonal Antibody HER2, Ogivri, Ontruzant, PF-05280014, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-qyyp, Trazimera
Mayo Clinic, National Cancer Institute (NCI)
Breast Adenocarcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Recurrent Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Breast Carcinoma, Refractory Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Nodal Marginal Zone Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage IV Breast Cancer AJCC v6 and v7
04/25
05/26
BP43131, NCT05219513: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Recruiting
1
200
Europe, US, RoW
RO7443904, Glofitamab, RO7082859, Obinutuzumab, Tocilizumab, Actemra
Hoffmann-La Roche
Lymphoma, Non-Hodgkin
04/25
04/25
NCT03983954: Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors

Hourglass Jan 2021 - Mar 2021 : First safety data from P1b trial in combination with Imfinzi for solid tumors
Hourglass Oct 2020 - Dec 2020 : Completion of P1b portion of p1b/2 trial in combination with Imfinzi for solid tumors
Active, not recruiting
1
60
RoW
Obinutuzumab pretreatment (Gazyva®) Naptumomab estafenatox (ABR-217620; NAP) and durvalumab (IMFINZI; MEDI4736), Naptumomab estafenatox (ABR-217620; NAP) and durvalumab (IMFINZI; MEDI4736)
NeoTX Therapeutics Ltd., AstraZeneca
ER+ Breast Cancer, Ovarian Cancer, Cervical Squamous Cell Carcinoma, Pancreatic Adenocarcinoma, Endometrial Cancer, Renal Cell Carcinoma, Urothelial Cancer, Head and Neck Squamous Cell Carcinoma, Mesothelioma, Melanoma, Hepatocellular Carcinoma, Prostate Cancer, NSCLC, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Bladder Cancer, Colorectal Cancer Metastatic, GastroEsophageal Cancer, NSCL2 Gene Mutation
10/26
10/26
SAVE, NCT04843904: Safe Accelerated Venetoclax Escalation in CLL

Recruiting
1
40
US
Venetoclax, Venclexta, Obinutuzumab, Gazyva, Rituximab, Rituxan
Dana-Farber Cancer Institute
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
06/25
06/30
NCT05653271: ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

Recruiting
1
42
US, RoW
Cyclophosphamide, Fludarabine, ACE1831, Obinutuzumab
Acepodia Biotech, Inc.
B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL, Primary Mediastinal Large B Cell Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma
09/25
09/27
NCT02457598: Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies

Active, not recruiting
1
203
Europe, US
Tirabrutinib, ONO/GS-4059, Idelalisib, Zydelig®, GS-1101, CAL-101, Entospletinib, GS-9973, Obinutuzumab
Gilead Sciences
B-cell Malignancies
12/25
12/25
NCT04599634: Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

Active, not recruiting
1
1
US
Obinutuzumab, Venetoclax, Magrolimab
National Cancer Institute (NCI)
Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Lymphoma, B-Cell Lymphoma
03/24
02/27
NCT05943496: Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia

Recruiting
1
25
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Echocardiography, EC, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Questionnaire Administration, Tafasitamab, Immunoglobulin, Anti-(Human Cd19 Antigen) (Human-mus musculus Monoclonal MOR00208 Heavy Chain), Disulfide with Human-mus musculus Monoclonal MOR00208 .Kappa.-chain, Dimer, Monjuvi, MOR-00208, MOR00208, MOR208, Tafasitamab-cxix, XmAb5574
OHSU Knight Cancer Institute, Oregon Health and Science University, Incyte Corporation
Chronic Lymphocytic Leukemia
01/26
01/27
CO43805, NCT05169515: A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

Recruiting
1
121
Europe, US, RoW
SC Mosunetuzumab, RO7030816, IV Glofitamab, RO7082859, CC-220, CC-99282, Obinutuzumab, RO5072759, Tocilizumab, RO4877533
Hoffmann-La Roche
Non-Hodgkin Lymphoma
07/26
07/28
 

Download Options